Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribavirin Dose Optimization in Hepatitis C
NCT01289496Phase 2Completed
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Feb 2011
- Primary completion
- Aug 2013
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of ribavirin in hepatitis C (HCV), sponsored by Centre hospitalier de l’Université de Montréal. Started Feb 2011; status: completed.
02
Drugs
ribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01289496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01289496.